Statistics from Altmetric.com
The EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (AAV)1 are a pillar in the treatment of patients with these diseases worldwide. Hence, it is of the utmost importance that information, especially dosing be correct and therefore reliable. More than in some other rheumatic diseases AAV oftentimes requires treatment from a multidisciplinary team. For physicians from other specialties dosing might not be as familiar as it is for rheumatologists.
Statement 7 of the recommendations suggests a dose of Methotrexate with 20–25 mg/kg/week for remission maintenance of AAV. This recommended dose would almost certainly be toxic and lead to complications or even death. Patients die every year from wrong dosing of Methotrexate.
I suggest that in the future, before publishing recommendations for the management of rheumatic diseases an additional layer of security be implemented by separate review of every suggested dose of every medication in the publication for mistakes or typos because every mistake, howsoever small, can have far reaching consequences for our patients.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.